大洋生物：5月13日召开业绩说明会，投资者参与

Group 1 - Company announced an earnings briefing on May 13, 2025 [1] - Company is actively applying and exploring the expansion of artificial intelligence in its operations [2] - The company is in the construction phase of the trifluoroacetyl series product project, which is an important raw material in the organic chemical field [6][29] Group 2 - The company aims to strengthen its potassium salt position, expand the fluorine industry, increase veterinary drug varieties, and enhance R&D capabilities as part of its development strategy [9] - The company is currently focusing on the semiconductor materials sector through its investment in Chip Pure Semiconductor [17] - The company reported a significant increase in sales revenue for Q1 2025, with a year-on-year growth of 27.78% [40] Group 3 - The company is considering mergers and acquisitions as part of its strategic planning [7][8] - The company is committed to improving its market valuation and investor returns despite current low market capitalization [13][26][39] - The company is monitoring the impact of new U.S. tariff policies, noting that its export sales to the U.S. are relatively small and have not had a significant negative impact [38]